This site uses both its own cookies and third-party cookies in order to obtain statistical data on the browsing activity of its users. You accept these cookies by continuing to browse the Portal or by clicking ACCEPT You can find information on how to enable/disable browser cookies reading our Cookie Policy

This site uses both its own cookies and third-party cookies (files which are installed on the user’s device and which record browsing information) in order to obtain statistical data on the browsing activity of its users. By clicking ACCEPT or by continuing to browse the Portal, you accept that PROMETUM SPAIN S.L.U. may store and use these cookies. To find out more, please read our Cookie Policy where you can also find information on how to enable/disable browser cookies. ACCEPT

You will receive an e-mail with instructions to reset your password
Home Hereditary cancers
icono oncologia.png

Hereditary cancers

What do we offer?

  • icono de laboratorioDetection of genes involved in predisposition to cancer: Breast - Ovary - Uterus - Prostate - Pancreatic - Stomach - Colorectal - Small intestine - Kidney - Duodenal - Melanoma - Neurofibromas - Central nervous syst. - Glioma - Optic - Endometrium - Thyroid - Sarcoma - Leukemias - Gastrointestinal - Genitourinary
  • icono de asesoramiento facultativoCounselling by a specialist before and after the analysis
  • icono de la muestraSample type: Collection of saliva through an oral swab
  • icono de tiempoResults in: 30 days*
  • 1 150 **
  • * Labour days counting from reception of the sample at the laboratory.
    ** Shipping charges included in peninsular Spain. Not included in Islands.

elige tu test genético

Why should you request this service?

What is the purpose of this analysis?

>
  • To detect if your DNA predisposes you to suffer any of those cancers.

  • If you suffer from a cancer, to detect if it will be pass on to your offspring and to customize your treatment

Should you do it?

>
  • You are in good health and have a family history:

    • 3 or more parents in the first degree (parents, children and siblings) or second-degree parents (grandparents and uncles) who have suffered the same cancer.

    • 2 first and / or second-level parents who have had cancer at a younger age than average.

    • Family history of a syndrome related to a hereditary predisposition to cancer.

    • Many parents with different cancers.

    • 1 or more family members with bilateral cancer.

    • 1 or more parents with multiple cancers whose primary cancer is unknown.

  • You are in good health with no family history, as part of a screening.

How does it work?

  1. elige tu test genético
    Choose your analysis and a healthcare professional will contact you in 48 hours
  2. frotis bucal para análisis
    You will receive a sample collector kit at home that will be picked up by a courier
  3. instrucciones de uso
    One of our partner labs will proceed to make the analysis
  4. instrucciones de uso
    Your healthcare professional will present your results by videoconference
go further

To go further:


Subtitles available in both English and French

Do you need more information?

  • What are the genes studied and what does it mean?>
      GEN OMIM or reference TYPE OF CANCER RELATED / TUMOR
      APC 611731 Colorectal, duodenal, others (AFP)
      ATM** 607585 Breast, pancreas
      BARD1 601593 Breast, ovary *
      BMPR1A 601299 Colorectal stomach and pancreas
      BRCA1** 113705 Breast, ovary, prostate, pancreas
      BRCA2** 600185 Breast, ovary, prostate, pancreas
      BRIP1 605882 Breast, ovary
      CDH1 192090 Breast, stomach, colorectal
      CDK4 123829 Melanoma
      CDKN2A 600160 Melanoma, pancreas
      CHEK2** 604373 Breast colorectal
      EPCAM 185535 Colorectal, uterus, others (S. Lynch)
      MLH1 120436 Colorectal, uterus, others (S. Lynch)
      MRE11A 600814 Mama, ovario*
      MSH2 609309 Colorectal, uterus, others (S. Lynch)
      MSH6 600678 Colorectal, uterus, others (S. Lynch)
      MUTYH 604933 Colorectal, uterus, others (S. Lynch)
      NBN 602667 Breast, ovary *
      NF1 162200 Neurofibromas, CNS, Optic Glioma, PGL / PCC
      PALB2 610355 Breast, pancreas
      PMS2 600259 Colorectal, uterus, others (S. Lynch)
      POLD1 612591 Colorectal endometrium
      POLE1 615083 colorectal
      PTEN 601728 Breast, uterus, kidney, thyroid, colorectal
      RAD50 604040 Breast, ovary *
      RAD51C 602774 Breast, ovary
      RAD51D 602954 Breast, ovary
      SMAD4 600993 Colorectal stomach and pancreas
      STK11 602216 Small intestine, colorectal, pancreas, breast, ovary
      TP53** 191170 Breast, sarcoma, CNS, leukemia, gastrointestinal, genitourinary
      * Possible association of both cancers.
      ** Includes analysis of up to 250 bp of untranslated region (UTR).
  • How to interpret the results?>
      POSITIVE NEGATIVE UNCERTAIN
      A mutation has been identified in a gene, which results in greater susceptibility to the disease. No mutation has been identified in the gene, so there is less risk that the patient will contract the disease. A genetic variant whose meaning is currently unknown has been identified.
      Increased risk Moderate risk Moderate risk but the patient must be monitored
  • Sensitivity and Specificity>

      These genes are analyzed by NGS techniques in combination with conventional approaches to molecular genetics when necessary. With this analysis, it is possible to detect point mutations in exons, in deep intronic regions (up to 45bp), in the untranslated regulatory regions of breast cancer-associated genes, as well as in some structural variants. However, this examination has some limitations, it is mainly known to present a high sensitivity and specificity (> 99%) as to the variations of simple nucleotides and small indels up to 9 nucleotides. Structural variants that affect only one exon present in coding exon genes may not be detected. For the rest of the major structural variants, the detection rate can reach up to 95%.

  • Guidelines>
    • Buttin, B. M., Powell, M. A., Mutch, D. G., Babb, S. A., Huettner, P. C., Edmonston, T. B., Herzog, T. J., Rader, J. S., Gibb, R. K., Whelan, A. J., Goodfellow, P. J. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am. J. Hum. Genet. 74: 1262-1269, 200
    • Chan, T. L., Yuen, S. T., Kong, C. K., Chan, Y. W., Chan, A. S. Y., Ng, W. F., Tsui, W. Y., Lo, M. W. S., Tam, W. Y., Li, V. S. W., Leung, S. Y. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nature Genet. 38: 1178-1183, 2006.
    • Frebourg, T., Kassel, J., Lam, K. T., Gryka, M. A., Barbier, N., Andersen, T. I., Borresen, A.-L., Friend, S. H. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc. Nat. Acad. Sci. 89: 6413-6417, 1992.
    • Online Mendelian Inheritance in Man, OMIM®. McKusick- Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), {24/04/2018}. World Wide Web URL: https://omim.org/

Any questions?

In compliance with the requirements of REGULATION (EU) 2016 / 679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 april 2016 on the protection of individuals with regard to the processing of personal data and the free movement of such data and repealing directive 95 / 46 / ec (general regulation of data protection), you are informed that ...